PCI – 7th June 2024
Thermofisher: Thu 29 February 2024, 11:15

Current Edition

Cell and Gene Therapy

Upcoming Events

Cell 2025 – 30.05.2025
Cell Leaders Awards – 30.05.2025
Biotechnology Show 2025: 20th January 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault – 18.03.2025
Biopharma Group – 19th March 2025

Mass Spectrometry Supports Development of New Oligonucleotide Therapeutics

Oligonucleotides’ ability to inhibit genes or to function as aptamers to interact with protein targets are increasingly vital research tools in the biopharmaceutical industry. Oligonucleotides target RNA at the cellular level, where
specific malfunctioning genes can be manipulated and/ or modulated. Anjali Alving of Bruker Scientific discusses  how this capability presents biopharma companies with opportunities to target diseases which have proven difficult to combat using classic small molecule approaches.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2020/07/Mass-Spectrometry-Supports-Development-of-New.pdf”]

Newcells 3 June 2024, 15:12
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
Tosoh – 29.04.25
Eppendorf – 18.03.2025
Asychem – 10.04.2025
Taconic Biosciences – 29.04.25
Steribar – 12.05.2025